Cory Renauer
Value, research analyst, biotech, small-cap

Exelixis And Cabozantinib: ASCO 2013 Highlights

Exelixis, Inc. (NASDAQ:EXEL) is a San Francisco based, oncology focused biotechnology company developing small molecule therapies for the treatment of cancer. It is heavily focused on its promising lead product Cometriq (cabozantinib). The FDA approved cabozantinib on November 29, 2012 for the treatment of progressive metastatic medullary thyroid cancer [MTC] and will likely expand its approval for treatment of several other cancers.

Exelixis intends to develop broadly-active cabozantinib "into a major oncology franchise." The drug is currently the subject of dozens of clinical studies, and was recently featured in 9 different presentations at the 2013 meeting of the American Society of Clinical Oncology [ASCO]. I'm going to break down several of the meeting's highlights that suggest the drug...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details